Iloprost is a prostacycline indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. It is available as injection for intravenous use. MedsAcross supplies Iloprost for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
AURLUMYN is a prostacyclin mimetic indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. Effectiveness was established in young, healthy adults who suffered frostbite at high altitudes.
Source: US FDA prescribing information
Iloprost is a synthetic analog of prostacyclin PGI 2. Iloprost is a vasodilator and inhibits platelet aggregation.
Source: US FDA prescribing information
Initiate intravenous infusion at 0.5 ng/kg/minute and titrate in 0.5 ng/kg/minute increments based on tolerability at intervals of 30 minutes to a maximum of 2 ng/kg/minute. Administer as continuous infusion for 6 hours each day up to a maximum of 8 consecutive days. Patients with moderate or severe hepatic impairment (Child-Pugh Class B or C): initiate infusion at 0.25 ng/kg/minute and titrate as described above. Patients with renal impairment with eGFR less than 30 mL/min: initiate infusion at 0.5 ng/kg/minute and titrate as described above. If the patient cannot tolerate the starting dose of 0.5 ng/kg/minute, the dose can be decreased to 0.25 ng/kg/minute. See Full Prescribing Information for instructions on preparation and administration.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
AURLUMYN may cause symptomatic hypotension. Monitor vital signs while initiating AURLUMYN. Correct hypotension prior to administration of AURLUMYN.
Source: US FDA prescribing information
Most common adverse events include headache, flushing, palpitations/tachycardia, nausea, vomiting, dizziness, and hypotension.
Source: US FDA prescribing information
Unopened vials of AURLUMYN are stable until the date indicated on the package when stored at 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Iloprost, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Aurlumyn 100 mcg/1 mL injectionIntravenous | BTG International | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Iloprost in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Iloprost and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Iloprost, including Aurlumyn.
Yes. The US FDA first approved Iloprost on 29 December 2004, according to Drugs@FDA.
Yes. Iloprost has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Iloprost is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Iloprost is classified under ATC code B01AC11 (Iloprost).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.